Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Cumulative doxorubicin dosage is a triggering factor for cognitive and physiological dysfunction?
Session:
Posters (Sessão 2 - Écran 3) - Ciência Básica
Speaker:
Filipa Machado
Congress:
CPC 2022
Topic:
O. Basic Science
Theme:
36. Basic Science
Subtheme:
36.2 Basic Science - Cardiac Biology and Physiology
Session Type:
Pósters Electrónicos
FP Number:
---
Authors:
Filipa Machado; Ângela Amaro-Leal; Ana i. Afonso; Isabel Rocha; Vera Geraldes
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt">Cognitive impairment in oncology (also called chemobrain) and anxiety disorders are<span style="color:black"> widely common complications of cancer therap</span>y with<span style="color:black"> doxorubicin (DOX). They</span> d<span style="color:black">ramatically deteriorate patients’ quality of life</span> by interfering with the control of different cognitive domains, changing various aspects of memory, emotion and executive function<span style="color:black">.</span> Despite the large number of studies addressing chemobrain physiological consequences, is not yet known the individual contribution of DOX treatment and cancer by themselves on the observed effects, since these adverse effects may be caused by cancer itself, cancer therapy, or both. Thus, in order to clarify DOX action on behavioral disturbances upon cumulative treatment, in this preliminary study on a healthy animal model, we determined the extension of doxorubicin effects due to various therapeutic doses on cognitive decline, anxiety, locomotor activity and cardiovascular parameters.</span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="color:black">For that, adult, normal weight, female Wistar rats were DOX-treated for 4 weeks: LDOX (</span>n=8; <span style="color:black">low dose, </span>2<span style="color:black">mg/kg/week), IDOX (n=8; intermediate dose, </span>4<span style="color:black">mg/kg/week), HDOX (n=8; high dose, </span>5<span style="color:black">mg/kg/week) and control (n=5; NaCl 0,9% <span style="background-color:white">saline solution; </span></span><span style="background-color:white">1ml/Kg/week</span><span style="color:black">). Behavioral tests of anxiety, locomotion, and exploration — open field test (OFT), elevated plus maze (EPM) and cognition performance (Y-maze) were accomplished. <span style="background-color:white">At the end of the protocol, animals were anaesthetized and blood pressure (BP), electrocardiogram, heart rate (HR) and respiratory frequency (RF) were recorded.</span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="color:black">Overall, our results showed that the three DOX dosages induced an anxiety-like behavior <span style="background-color:white">and locomotor activity impairments. </span>Moreover, DOX treatment, independent of the dosage, induced hypolocomotion which was <span style="background-color:white">accompanied by hypoactivity. In addition, HDOX dosage </span>caused <span style="background-color:white">short-term memory (HDOX: 16.7±6.2 % vs. CTR: 37.9±3.3%). All these behavioral changes were accompanied by a significant change in physiological parameters, such as </span>hypotension (LDOX: 128±4 mmHg; IDOX: 90±10 mmHg; HDOX: 76±12 mmHg vs<em>.</em> CTR: 129±3 mmHg) and bradycardia (LDOX: 381±18 bpm; IDOX: 288±22 bpm; HDOX: 296±35<em> </em>bpm<em> </em>vs<em>.</em> CTR: 379±22 bpm). </span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="color:black">These findings suggest that the DOX effects on behavioral function are different according to the cumulative dosage, with the highest dosage causing the most deleterious effects on the behavioral and physiological parameters evaluated. Although further studies are needed to assess the effect of cancer itself on the etiology of the behavioral impairment, these results support the hypothesis </span></span><span style="font-size:12.0pt">that doxorubicin itself <span style="color:black">contributes to the etiology of cognitive symptomatology in humans, also named “chemobrain”. </span></span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site